In this context, we have recently generated targeted nanoliposomal formulations carrying ALK-directed siRNAs (TL[ALK-siRNA]), which are highly specific for the gene target [21, 22] and efficiently delivered to NB cells thanks to a selective tumor targeting provided by the carrier [24, 39]. Here, ALK is linked to neoplasm.